Condition: Cholangiocarcinoma,Adult
Intervention: Drug: 3D185
Sponsor: 3D Medicines (Beijing) Co., Ltd.
Not yet recruiting
Feeds
6810 items (6810 unread) in 74 feeds
Acinar Cell Carcinoma
(81 unread)
Acinic Cell Carcinoma
(46 unread)
Adenoid Cystic Carcinoma
(159 unread)
Adrenal Gland Cancer
(533 unread)
Ampulla Of Vater
(68 unread)
Anal Cancer
(425 unread)
Angiosarcoma
(153 unread)
Appendix Cancer
(104 unread)
Bile Duct Cancer
(845 unread)
Brain and CNS
(878 unread)
Carcinoid
(266 unread)
Endocrine/Neuroendocrine
(808 unread)
Gall Bladder Cancer
(381 unread)
Hemangioendothelioma
(215 unread)
Hepatoblastoma
(129 unread)
Pancreas
(117 unread)
Phyllodes
(105 unread)
PMP and Mucinous Tumors
(114 unread)
Rhabdomyosarcoma
(246 unread)
Sarcoma
(1137 unread)
Trial - Cholangiocarcinoma (40 unread)
-
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma
Posted: September 10th, 2021, 2:00pm GMT
-
RFA Combined With Chemotherapy for Unresectable Cholangiocarcinoma
Posted: August 31st, 2021, 2:00pm GMT
Condition: Cholangiocarcinoma
Interventions: Device: radiofrequency ablation; Drug: Chemotherapy drug
Sponsors: First People's Hospital of Hangzhou; Hangzhou Cancer Hospital; Changhai Hospital; Eastern Hepatobiliary Surgery Hospital; Chinese Academy of Medical Sciences; Xijing Hospital
Recruiting -
Biliary Drainage Plus HAIC in Locally Advanced pCCA
Posted: August 27th, 2021, 2:00pm GMT
Condition: Perihilar Cholangiocarcinoma
Interventions: Drug: oxaliplatin and 5-fluorouracil; Procedure: Biliary Drainage; Other: Best Supportive Care; Procedure: External biliary drainage
Sponsor: Peking University
Not yet recruiting -
GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC
Posted: August 25th, 2021, 2:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Intervention: Drug: GP+PD-1+Tight
Sponsor: Fudan University
Not yet recruiting -
Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
Posted: August 18th, 2021, 2:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: cryoablation; Drug: Sintilimab; Drug: lenvatinib
Sponsor: Fudan University
Recruiting -
Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer
Posted: August 18th, 2021, 2:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Sintilimab; Drug: Lenvatinib
Sponsor: Fudan University
Recruiting -
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
Posted: August 18th, 2021, 2:00pm GMT
Conditions: Advanced Biliary Tract Cancer; Intrahepatic Cholangiocarcinoma; Extrahepatic Cholangiocarcinoma; Gallbladder Carcinoma
Interventions: Drug: Irinotecan Liposome Injection; Drug: SG001; Drug: Fluorouracil; Drug: Leucovorin
Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.
Not yet recruiting -
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005)
Posted: August 16th, 2021, 2:00pm GMT
Conditions: Uterine Cervical Neoplasms; Endometrial Neoplasms; Squamous Cell Carcinoma of Head and Neck; Gallbladder Neoplasms; Cholangiocarcinoma; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Hepatocellular Carcinoma
Interventions: Biological: Pembrolizumab/Vibostolimab Co-Formulation; Biological: Pembrolizumab; Drug: Lenvatinib; Drug: 5-Fluorouracil; Drug: Cisplatin; Drug: Paclitaxel
Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting -
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±)
Posted: August 11th, 2021, 2:00pm GMT
Conditions: Ovarian Cancer; Ovarian Neoplasms; Ovarian Carcinoma; Endometrial Cancer; Colorectal Cancer; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma; TNBC - Triple-Negative Breast Cancer; Triple Negative Breast Cancer; Cholangiocarcinoma; Bile Duct Cancer; Colon Cancer; Colon Cancer Stage; Colon Neoplasm; Colon Adenocarcinoma; Colon Rectal Cancer; Colon Cancer Liver Metastasis; Colorectal Neoplasms; Colorectal Carcinoma; Colorectal Adenocarcinoma; Colorectal Cancer Metastatic; Colorectal Cancer Stage IV; Rectum Cancer; Rectum Neoplasm; Rectum Carcinoma; Rectal Cancer; Rectal Neoplasms; Rectal Adenocarcinoma; Rectal Cancer Stage; Rectal Cancer Metastatic; Rectal Cancer Stage III; Esophagus Cancer; Esophageal Cancer; Esophageal Neoplasms; Gastric Cancer Stage; Breast Cancer; Breast Neoplasm; Breast Adenocarcinoma; Breast Cancer Stage IV; Breast Cancer Stage; Breast Cancer Metastatic; Breast Cancer Invasive; Triple Negative Breast Neoplasms; Intrahepatic Cholangiocarcinoma; Intrahepatic Cholangiocarcinoma Recurrent; Hilar Cholangiocarcinoma; Distal Cholangiocarcinoma; Ovary Cancer; Ovary Neoplasm; Ovary Disease; Ovary Metastasis; Ovarian Diseases; Ovarian Cancer Stage; Ovarian Epithelial Cancer; Ovarian Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Neoplasm Epithelial; Ovarian Cancer Recurrent; Endometrial Diseases; Endometrial Adenocarcinoma; Endometrial Carcinosarcoma; Endometrial Clear Cell Adenocarcinoma; Endometrioid Adenocarcinoma; Endometrial Neoplasms; Endometrial Cancer Recurrent; Endometrioid Tumor; Fallopian Tube Cancer; Peritoneal Cancer
Intervention: Drug: ELU001
Sponsor: Elucida Oncology
Recruiting -
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Posted: August 11th, 2021, 2:00pm GMT
Conditions: Bile Duct Cancer; Gall Bladder Cancer; Breast Cancer; Neuroendocrine Tumors; Ovarian Cancer; Pancreatic Adenocarcinoma; Soft Tissue Sarcoma; Vulvar Cancer; Prostate Cancer
Interventions: Drug: Atezolizumab; Drug: Tivozanib
Sponsors: University of Florida; Genentech, Inc.; Aveo Oncology Pharmaceuticals
Not yet recruiting -
Liver Transplantation for Non-resectable Perihilar Cholangiocarcinoma
Posted: August 6th, 2021, 2:00pm GMT
Conditions: Perihilar Cholangiocarcinoma; Klatskin Tumor; Bile Duct Cancer
Intervention: Procedure: Liver transplant
Sponsor: Oslo University Hospital
Recruiting -
Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)
Posted: August 4th, 2021, 2:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Drug: Novel combination of chemotherapy and immunotherapy
Sponsor: University of Alabama at Birmingham
Not yet recruiting -
A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation
Posted: July 22nd, 2021, 2:00pm GMT
Condition: Solid Tumors, KRAS Mutation
Interventions: Drug: BI 1823911; Drug: BI 1701963; Drug: Midazolam
Sponsor: Boehringer Ingelheim
Recruiting -
The ID- RFA Trial: A Trial of Intraductal Radio-frequency Ablation (ID-RFA) Plus Biliary Stenting Versus Biliary Stenting Alone for the Treatment of Malignant Biliary Obstruction.
Posted: June 28th, 2021, 2:00pm GMT
Condition: Malignant Biliary Obstruction
Interventions: Procedure: Intraductal Radio-Frequency Ablation; Device: Biliary Stent Placement
Sponsors: University Hospitals Dorset NHS Foundation Trust; Aquilant Services; The Christie NHS Foundation Trust
Not yet recruiting -
Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors
Posted: June 3rd, 2021, 2:00pm GMT
Condition: Solid Tumor
Intervention: Drug: utidelone injection
Sponsors: Beijing Biostar Technologies, Ltd; Chengdu Biostar Pharmaceuticals, Ltd
Recruiting -
Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer
Posted: January 27th, 2021, 3:00pm GMT
Conditions: Biliary Tract Cancer; Cholangiocarcinoma
Intervention: Drug: Bintrafusp alfa
Sponsors: AIO-Studien-gGmbH; Merck Serono GmbH, Germany
Recruiting -
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Posted: December 9th, 2020, 3:00pm GMT
Conditions: HER2-positive; Adenocarcinoma; Bile Duct Cancer; Biliary Tract Cancer; Bladder Cancer; Breast Cancer; Breast Neoplasm; Carcinoma, Ductal; Carcinoma, Hepatocellular; Cancer; Lung Cancer, Non-Small-Cell; Carcinoma, Ovarian Epithelial; Carcinoma, Small Cell; Carcinoma, Squamous; Carcinoma, Transitional Cell; Colorectal Cancer; Esophagogastric Junction Neoplasms; Inflammatory Breast Cancer; Stomach Neoplasms; Malignant Neoplasms; Ovarian Neoplasms; Pancreatic Cancer; HER2-positive Solid Tumors; HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER-2 Protein Overexpression; HER-2 Gene Amplification; Prostate Cancer; Head and Neck Cancer; Endometrial Cancer; Lung Cancer, Small Cell
Intervention: Biological: CT-0508
Sponsor: Carisma Therapeutics Inc
Recruiting -
Evaluating Safety and Efficacy of Tivozanib (AV-951) in Cholangiocarcinoma
Posted: November 27th, 2020, 3:00pm GMT
Conditions: Cholangiocarcinoma; Bile Duct Neoplasm; Biliary Tract Malignancy
Intervention: Drug: Tivozanib
Sponsor: National Cancer Institute (NCI)
Not yet recruiting -
Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
Posted: September 28th, 2020, 2:00pm GMT
Conditions: Bile Duct Cancer; Biliary Cancer; Biliary Tract Neoplasms; Cholangiocarcinoma
Interventions: Drug: Trametinib; Drug: Hydroxychloroquine
Sponsor: National Cancer Institute (NCI)
Recruiting -
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Posted: September 28th, 2020, 2:00pm GMT
Conditions: Pancreatic Cancer; Small Bowel Cancer; Colorectal Cancer; Melanoma; Non Small Cell Lung Cancer; Thyroid Cancer; Bladder Cancer; Head and Neck Cancer; Gastric Cancer; Esophageal Cancer; Cholangiocarcinoma; Ovarian Cancer; Hepatocellular Carcinoma; Glioblastoma; MAPK Gene Mutation; KRAS Activating Mutation; BRAF Gene Mutation; NRAS Gene Mutation; HRAS Gene Mutation; MEK Mutation; ERK Mutation
Intervention: Drug: Ulixertinib (BVD-523)
Sponsors: xCures; Cancer Commons
Available -
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 Mutations
Posted: August 20th, 2020, 2:00pm GMT
Conditions: Cholangiocarcinoma; Chondrosarcoma; Glioma; Any Solid Tumor
Intervention: Drug: LY3410738
Sponsors: Eli Lilly and Company; Loxo Oncology, Inc.
Recruiting -
Liver Cancer Registry Platform
Posted: August 12th, 2020, 2:00pm GMT
Conditions: Hepatocellular Carcinoma (HCC); Cholangiocarcinoma
Intervention: Other: Physician's choice according to patient's needs.
Sponsor: iOMEDICO AG
Recruiting -
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
Posted: July 30th, 2020, 2:00pm GMT
Conditions: Advanced Bile Duct Carcinoma; Advanced Breast Carcinoma; Advanced Cervical Carcinoma; Advanced Endometrial Carcinoma; Advanced Esophageal Carcinoma; Advanced Gastric Carcinoma; Advanced Head and Neck Carcinoma; Advanced Lung Non-Small Cell Carcinoma; Advanced Lung Small Cell Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Penile Carcinoma; Advanced Pleural Malignant Mesothelioma; Advanced Urothelial Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IVA Gastric Cancer AJCC v8; Clinical Stage IVB Gastric Cancer AJCC v8; Pathologic Stage III Gastric Cancer AJCC v8; Pathologic Stage IIIA Gastric Cancer AJCC v8; Pathologic Stage IIIB Gastric Cancer AJCC v8; Pathologic Stage IIIC Gastric Cancer AJCC v8; Pathologic Stage IV Gastric Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Stage III Cervical Cancer AJCC v8; Stage III Distal Bile Duct Cancer AJCC v8; Stage III Intrahepatic Bile Duct Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Penile Cancer AJCC v8; Stage III Pleural Malignant Mesothelioma AJCC v8; Stage IIIA Cervical Cancer AJCC v8; Stage IIIA Distal Bile Duct Cancer AJCC v8; Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Penile Cancer AJCC v8; Stage IIIA Pleural Malignant Mesothelioma AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Cervical Cancer AJCC v8; Stage IIIB Distal Bile Duct Cancer AJCC v8; Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIB Penile Cancer AJCC v8; Stage IIIB Pleural Malignant Mesothelioma AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IV Cervical Cancer AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Intrahepatic Bile Duct Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Pleural Malignant Mesothelioma AJCC v8; Stage IVA Cervical Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVB Cervical Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Triple-Negative Breast Carcinoma; Unresectable Urothelial Carcinoma
Interventions: Drug: Cisplatin; Drug: Elimusertib; Drug: Gemcitabine Hydrochloride
Sponsor: National Cancer Institute (NCI)
Recruiting -
Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
Posted: March 10th, 2020, 2:00pm GMT
Condition: Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Durvalumab; Drug: SNDX-6352
Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Syndax Pharmaceuticals; AstraZeneca
Recruiting -
A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion
Posted: January 23rd, 2020, 3:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Drug: E7090
Sponsor: Eisai Co., Ltd.
Recruiting -
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer
Posted: November 15th, 2019, 3:00pm GMT
Condition: Biliary Tract Cancer
Interventions: Drug: NUC-1031; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: NuCana plc
Recruiting -
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer
Posted: October 30th, 2019, 2:00pm GMT
Conditions: Hepatocellular Carcinoma; Liver Cancer; Cholangiocarcinoma
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting -
A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer
Posted: October 24th, 2019, 2:00pm GMT
Conditions: Gastrointestinal Neoplasms; Cholangiocarcinoma; Pancreatic Neoplasms
Intervention: Drug: BI 905711
Sponsor: Boehringer Ingelheim
Recruiting -
Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC)
Posted: October 21st, 2019, 2:00pm GMT
Condition: Primary Sclerosing Cholangitis
Interventions: Drug: Simvastatin 40mg; Drug: Placebo oral tablet
Sponsor: Annika Bergquist
Recruiting -
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
Posted: January 14th, 2019, 3:00pm GMT
Conditions: Colon Cancer; Pancreatic Cancer; Cholangiocarcinoma; Mestatic Colon Carcinoma; Liver Metastasis
Interventions: Drug: MVT-5873; Procedure: pancreatectomy or hepatectomy
Sponsor: National Cancer Institute (NCI)
Recruiting -
Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma
Posted: July 27th, 2018, 2:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Drug: mFOLFOXIRI
Sponsor: Khon Kaen University
Recruiting -
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Posted: July 26th, 2018, 2:00pm GMT
Conditions: HER2-positive Breast Cancer; HER2 Gene Mutation; HER-2 Gene Amplification; HER2 Positive Gastric Cancer; Salivary Gland Cancer; Salivary Gland Tumor; Salivary Gland Carcinoma; Salivary Gland Neoplasms; Lung Cancer; Colo-rectal Cancer; Rare Diseases; Solid Tumor; Recurrent Gastric Cancer; Recurrent Colon Cancer; Recurrent Breast Cancer; Head and Neck Cancer; Head and Neck Carcinoma; Bladder Cancer; Cervical Cancer; Liver Cancer; Bile Duct Cancer; Urologic Cancer; Pancreatic Cancer; Prostate Cancer; Recurrent Prostate Cancer; Rectal Cancer; Recurrent Ovarian Carcinoma; Recurrent Renal Cell Cancer; Rectal Cancer Stage II; Rectal Cancer Stage I; Rectal Cancer Stage III; Skin Cancer; Mouth Cancer; Lip Cancer Stage I; Tongue Cancer; Breast Neoplasm Malignant Primary; Larynx Cancer; Tonsil Cancer; Palate Cancer; Mucoepidermoid Carcinoma; Primary Peritoneal Carcinoma; Mucinous Adenocarcinoma Gastric; Mucinous Breast Cancer Recurrent; Cholangiocarcinoma
Intervention: Drug: A166
Sponsor: Klus Pharma Inc.
Recruiting -
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Posted: November 6th, 2017, 3:00pm GMT
Conditions: Melanoma; Non-small Cell Lung Cancer; Breast Cancer; Gastric Cancer; Renal Cell Carcinoma; Ovarian Cancer; Cholangiocarcinoma; Bladder Urothelial Carcinoma; Pancreatic Adenocarcinoma; Colorectal Cancer; Esophageal Cancer; Hepatic Cancer; Head and Neck Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer; Other Solid Tumors; Diffuse Large B-cell Lymphoma (DLBCL); Mantle Cell Lymphoma; Indolent B-cell Lymphomas; Non-Hodgkin Lymphoma; Follicular Lymphoma; Lymphoplasmacytic Lymphoma; Waldenstrom's Disease; Marginal Zone Lymphoma; Mucosa Associated Lymphoid Tissue; Small Lymphocytic Leukemia
Interventions: Drug: CDX-1140; Drug: CDX-301; Drug: Pembrolizumab; Drug: Chemotherapy
Sponsors: Celldex Therapeutics; Merck Sharp & Dohme Corp.
Recruiting -
Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
Posted: July 11th, 2017, 2:00pm GMT
Conditions: Advanced Malignant Solid Neoplasm; Glioblastoma; Recurrent Cholangiocarcinoma; Recurrent Glioma; Recurrent Malignant Solid Neoplasm; WHO Grade II Glioma; WHO Grade III Glioma
Intervention: Drug: Olaparib
Sponsor: National Cancer Institute (NCI)
Recruiting -
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Posted: July 15th, 2016, 2:00pm GMT
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Breast Metaplastic Carcinoma; Cervical Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Solid Neoplasm; Malignant Testicular Sex Cord-Stromal Tumor; Metastatic Malignant Neoplasm of Unknown Primary; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
Interventions: Procedure: Biospecimen Collection; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting -
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Posted: July 4th, 2016, 2:00pm GMT
Conditions: Biliary Tract Neoplasms; Liver Cancer; Hepatocellular Carcinoma; Cholangiocarcinoma; Bile Duct Cancer
Interventions: Drug: Durvalumab; Drug: Tremelimumab; Procedure: TACE; Procedure: RFA; Procedure: Cryoablation
Sponsor: National Cancer Institute (NCI)
Recruiting -
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Posted: October 5th, 2015, 2:00pm GMT
Conditions: Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, Anaplastic; Melanoma; Neuroendocrine Tumors; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Primary Brain Tumors; Renal Cell Carcinoma; Sarcomas; Salivary Gland Cancers; Adult Solid Tumor
Intervention: Drug: Entrectinib
Sponsor: Hoffmann-La Roche
Recruiting -
90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
Posted: July 31st, 2015, 2:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Device: SIR-Spheres microspheres (Yttrium-90 Microspheres); Drug: Gemcitabine; Drug: Cisplatin
Sponsor: Medical University of South Carolina
Recruiting -
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
Posted: March 4th, 2015, 3:00pm GMT
Conditions: Adult Hepatocellular Carcinoma; Resectable Hepatocellular Carcinoma; Cholangiocarcinoma; Benign Liver Tumor; Metastases to Liver
Interventions: Biological: Fluorine F 18 L-glutamate Derivative 18F-FSPG; Biological: Carbon C 11 Acetate; Procedure: Positron Emission Tomography; Other: Laboratory Biomarker Analysis; Biological: Fluorine F 18 2-deoxy-2-(18F)fluoro-D-glucose
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Not yet recruiting -
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
Posted: August 2nd, 2013, 2:00pm GMT
Conditions: Colorectal Neoplasms; Gastric Neoplasms; Cholangiocarcinoma; Bile Duct Cancer; Pancreas Cancer
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting